166 related articles for article (PubMed ID: 22396745)
1. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
Lam YM; McBride KL; Amin J; Cordery DV; Kelleher AD; Cooper DA; Koelsch KK
PLoS One; 2012; 7(3):e31990. PubMed ID: 22396745
[TBL] [Abstract][Full Text] [Related]
2. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
[TBL] [Abstract][Full Text] [Related]
3. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
[TBL] [Abstract][Full Text] [Related]
4. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
Hatano H; Strain MC; Scherzer R; Bacchetti P; Wentworth D; Hoh R; Martin JN; McCune JM; Neaton JD; Tracy RP; Hsue PY; Richman DD; Deeks SG
J Infect Dis; 2013 Nov; 208(9):1436-42. PubMed ID: 23975885
[TBL] [Abstract][Full Text] [Related]
5. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
[TBL] [Abstract][Full Text] [Related]
6. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
Gandhi RT; Zheng L; Bosch RJ; Chan ES; Margolis DM; Read S; Kallungal B; Palmer S; Medvik K; Lederman MM; Alatrakchi N; Jacobson JM; Wiegand A; Kearney M; Coffin JM; Mellors JW; Eron JJ;
PLoS Med; 2010 Aug; 7(8):. PubMed ID: 20711481
[TBL] [Abstract][Full Text] [Related]
7. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
[TBL] [Abstract][Full Text] [Related]
8. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
Delaugerre C; Charreau I; Braun J; Néré ML; de Castro N; Yeni P; Ghosn J; Aboulker JP; Molina JM; Simon F;
AIDS; 2010 Sep; 24(15):2391-5. PubMed ID: 20683319
[TBL] [Abstract][Full Text] [Related]
9. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
[TBL] [Abstract][Full Text] [Related]
10. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.
Grant PM; Palmer S; Bendavid E; Talbot A; Slamowitz DC; Cain P; Kobayashi SS; Balamane M; Zolopa AR
J Clin Virol; 2009 Dec; 46(4):305-8. PubMed ID: 19819183
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.
Caby F; Schneider L; Blanc C; Soulié C; Tindel M; Peytavin G; Agher R; Valantin MA; Tubiana R; Wirden M; Calvez V; Marcelin AG; Katlama C
Infection; 2014 Apr; 42(2):295-301. PubMed ID: 24155032
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy.
Charpentier C; Piketty C; Laureillard D; Tisserand P; Si-Mohamed A; Weiss L; Bélec L
Eur J Clin Microbiol Infect Dis; 2012 Feb; 31(2):129-33. PubMed ID: 21559766
[TBL] [Abstract][Full Text] [Related]
15. Modelling HIV-1 2-LTR dynamics following raltegravir intensification.
Luo R; Cardozo EF; Piovoso MJ; Wu H; Buzon MJ; Martinez-Picado J; Zurakowski R
J R Soc Interface; 2013 Jul; 10(84):20130186. PubMed ID: 23658114
[TBL] [Abstract][Full Text] [Related]
16. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
[TBL] [Abstract][Full Text] [Related]
17. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK;
J Virol; 2014 Mar; 88(6):3516-26. PubMed ID: 24403590
[TBL] [Abstract][Full Text] [Related]
18. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Buzón MJ; Massanella M; Llibre JM; Esteve A; Dahl V; Puertas MC; Gatell JM; Domingo P; Paredes R; Sharkey M; Palmer S; Stevenson M; Clotet B; Blanco J; Martinez-Picado J
Nat Med; 2010 Apr; 16(4):460-5. PubMed ID: 20228817
[TBL] [Abstract][Full Text] [Related]
20. Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy.
Wang X; Mink G; Lin D; Song X; Rong L
J Theor Biol; 2017 Mar; 416():16-27. PubMed ID: 28025011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
